CTLA4 and nonpapillary renal cell carcinoma: Recently, new targeted therapies (such as with tyrosine kinase inhibitors) and immunotherapies (such as with anti‐PD‐1/L1 and ‐CTLA4 antibodies) have shown efficacy in the treatment of metastatic ccRCC patients with unresectable ccRCC.6, 9, 10, 11